{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:11:38Z","timestamp":1792181498032,"version":"4.4.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"abstract":"<jats:p>This study conducts a rapid health technology assessment to systematically evaluate the effectiveness, safety, and cost-effectiveness of Cerebrolysin as an adjunctive therapy for acute ischemic stroke to provide evidence-based medicine for clinical decisions of Cerebrolysin. All systematic reviews\/meta-analyses, pharmacoeconomic studies, and health technology assessment reports of Cerebrolysin for the treatment of acute ischemic stroke before August 17, 2023, were retrieved from PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang, Weipu, Sinomed database and the official website of health technology assessment. According to the inclusion and exclusion criteria, 2 researchers independently carried out screening, data extraction, and quality evaluation and descriptively analyzed the results of the included studies. A total of 14 pieces of literature were incorporated, comprising 8 systematic reviews\/meta-analyses and 6 pharmacoeconomic studies. In terms of effectiveness, compared to control groups, the use of Cerebrolysin as a treatment for acute ischemic stroke demonstrates certain advantages, including enhancement in total efficacy rate, neurological function, upper limb motor dysfunction, and facilitation of the recovery of activities of daily living. Especially in patients with moderate to severe acute ischemic stroke, Cerebrolysin has demonstrated the ability to enhance neurological function recovery and ameliorate disabilities. Regarding safety, adverse reactions were mild or comparable to those in the control group. The primary findings of economic studies reveal that advocating for the use of Cerebrolysin offers certain cost-effectiveness advantages. Cerebrolysin contributes to improved clinical efficacy and evaluation indexes while demonstrating favorable safety and economic benefits.<\/jats:p>","DOI":"10.1097\/md.0000000000037593","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T18:01:39Z","timestamp":1711735299000},"page":"e37593","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment"],"prefix":"10.1097","volume":"103","author":[{"given":"Miaomiao","family":"Wan","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonghao","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of First Clinical Medical, Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Yang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Guangxi Medical University, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wei","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Guangxi Medical University, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqian","family":"He","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Guangxi Medical University, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6809-5629","authenticated-orcid":false,"given":"Xia","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/17474930211065917","article-title":"World Stroke Organization (WSO): global stroke fact sheet 2022.","volume":"17","author":"Feigin","year":"2022","journal-title":"Int J Stroke"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1212\/WNL.0000000000207387","article-title":"Global burden, risk factor analysis, and prediction study of ischemic stroke, 1990-2030.","volume":"101","author":"Fan","year":"2023","journal-title":"Neurology"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/CCM.0000000000004597","article-title":"Management of acute ischemic stroke.","volume":"48","author":"Herpich","year":"2020","journal-title":"Crit Care Med"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/ijms24054334","article-title":"Neuroprotective strategies for ischemic stroke-future perspectives.","volume":"24","author":"Haupt","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.3390\/ijms130911753","article-title":"Neuroprotection for stroke: current status and future perspectives.","volume":"13","author":"Minnerup","year":"2012","journal-title":"Int J Mol Sci"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10072-021-05089-2","article-title":"Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.","volume":"42","author":"Fiani","year":"2021","journal-title":"Neurol Sci"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14737175.2018.1500459","article-title":"Cerebrolysin: a multi-target drug for recovery after stroke.","volume":"18","author":"Brainin","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"R8-20250503","first-page":"281","article-title":"Chinese expert consensus on emergency diagnosis and treatment of acute ischemic stroke: a expert consensus from National Health Commission Emergency Medicine Quality Control Center, Chinese Medical Association Emergency Physicians Branch\/World Federation of Chinese Medicine Societies Emergency Committee [Chinese].","volume":"38","author":"Fang","year":"2018","journal-title":"Chin J Crit Care Med"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1111\/ene.14936","article-title":"European academy of neurology and European federation of neurorehabilitation societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke.","volume":"28","author":"Beghi","year":"2021","journal-title":"Eur J Neurol"},{"key":"R12-20250503","first-page":"187","article-title":"Health technology assessment.","volume":"47","author":"Hailey","year":"2006","journal-title":"Singapore Med J"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1017\/S0266462308080483","article-title":"Rapid reviews versus full systematic reviews: an inventory of current methods and practice in health technology assessment.","volume":"24","author":"Watt","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.2022.1420","article-title":"What is acute ischemic stroke?","volume":"327","author":"Walter","year":"2022","journal-title":"JAMA"},{"key":"R15-20250503","first-page":"1","article-title":"Efficacy and safety of cerebrolysin for acute ischemic stroke: a meta-analysis of randomized controlled trials.","volume":"2017","author":"Zhang","year":"2017","journal-title":"Biomed Res Int"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2147\/DDDT.S124273","article-title":"Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials.","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10072-017-3214-0","article-title":"Safety and efficacy of cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.","volume":"39","author":"Bornstein","year":"2018","journal-title":"Neurol Sci"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s10072-017-3037-z","article-title":"Safety and efficacy of cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials.","volume":"38","author":"Guekht","year":"2017","journal-title":"Neurol Sci"},{"key":"R19-20250503","first-page":"4233","article-title":"Efficacy and safety of cerebrolysin in adjuvant treatment of acute cerebral infarction: a systematic review [Chinese].","volume":"28","author":"Tang","year":"2017","journal-title":"China Pharm"},{"key":"R20-20250503","first-page":"43","article-title":"Efficacy and safety of cerebroprotein hydrolysate in the treatment of acute ischaemic stroke: a meta-analysis [Chinese].","volume":"5","author":"Yu","year":"2018","journal-title":"J Chin Res Hospitals"},{"key":"R21-20250503","first-page":"CD007026","article-title":"Cerebrolysin for acute ischaemic stroke.","volume":"7","author":"Ziganshina","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/ph14121297","article-title":"Safety of cerebrolysin for neurorecovery after acute ischemic stroke: a systematic review and meta-analysis of twelve randomized-controlled trials.","volume":"14","author":"Strilciuc","year":"2021","journal-title":"Pharmaceuticals"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jbmt.2013.11.006","article-title":"Stroke-related motor outcome measures: do they quantify the neurophysiological aspects of upper extremity recovery?","volume":"18","author":"Pandian","year":"2014","journal-title":"J Bodyw Mov Ther"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"105033","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105033","article-title":"Relationship of Barthel Index and its short form with the modified Rankin Scale in acute stroke patients.","volume":"29","author":"Liu","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R25-20250503","first-page":"101","article-title":"Cost-effectiveness analysis of three drug regimens for acute cerebrovascular disease [Chinese].","volume":"16","author":"Lin","year":"2004","journal-title":"Strait Pharm J"},{"key":"R26-20250503","first-page":"411","article-title":"Analysis of cost-effectiveness of three therapeutic schemes for cerebral infarction [Chinese].","volume":"19","author":"Zhang","year":"2010","journal-title":"Chin J Pharmacoepidemiol"},{"key":"R27-20250503","first-page":"82","article-title":"Cost-effectiveness analysis of ganglioside and cerebroprotein hydrolysate in the treatment of acute cerebral infarction [Chinese].","volume":"10","author":"Li","year":"2013","journal-title":"J North Pharm"},{"key":"R29-20250503","first-page":"14","article-title":"The pharmacoeconomic evaluation of cerebroprotein hydrolysate for injection in curing of acute cerebral infarction [Chinese].","volume":"12","author":"He","year":"2017","journal-title":"China J Pharm Economics"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/healthcare11101497","article-title":"Cost-effectiveness of cerebrolysin after ischemic stroke: secondary analysis of the CARS study.","volume":"11","author":"Strilciuc","year":"2023","journal-title":"Healthcare"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"2654729","DOI":"10.1155\/2022\/2654729","article-title":"Effects of all-Inclusive and hierarchical rehabilitation nursing model combined with acupuncture on limb function and quality of life in elderly patients with cerebral infarction during convalescence.","volume":"2022","author":"Zuo","year":"2022","journal-title":"J Healthc Eng"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1474-4422(06)70495-1","article-title":"Clinical interpretation and use of stroke scales.","volume":"5","author":"Kasner","year":"2006","journal-title":"Lancet Neurol"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2019.01.017","article-title":"Prospective, double blinded, comparative assessment of the pharmacological activity of cerebrolysin and distinct peptide preparations for the treatment of embolic stroke.","volume":"398","author":"Zhang","year":"2019","journal-title":"J Neurol Sci"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/s-0039-1700790","article-title":"Efficacy of neuroprotective drugs in acute ischemic stroke: is it helpful?","volume":"10","author":"Mehta","year":"2019","journal-title":"J Neurosci Rural Pract"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"115","DOI":"10.17116\/jnevro2020120041115","article-title":"Cognitive rehabilitation of patients with focal brain damage.","volume":"120","author":"Bogolepova","year":"2020","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3892\/etm.2016.3139","article-title":"Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke.","volume":"11","author":"Xue","year":"2016","journal-title":"Exp Ther Med"},{"key":"R39-20250503","first-page":"CD007026","article-title":"Cerebrolysin for acute ischaemic stroke.","volume":"4","author":"Ziganshina","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5797\/jnet.ra.2023-0035","article-title":"A review on adjunctive therapies for endovascular treatment in acute ischemic stroke.","volume":"17","author":"Goyal","year":"2023","journal-title":"J Neuroendovasc Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:01:45Z","timestamp":1746313305000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":38,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037593","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}